The HNRNPF Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the HNRNPF gene in human HeLa cells. This pooled loss-of-function model provides a versatile tool for examining the consequences of HNRNPF ablation without the clonal selection artifacts associated with monoclonal lines, preserving the natural heterogeneity of the engineered population. By targeting the HNRNPF locus through CRISPR-mediated gene disruption, researchers can systematically study its functional contributions to pre-mRNA processing and alternative splicing regulation.
HeLa cells are a well-established human cervical epithelial adenocarcinoma line, originally derived from a patient with cervical cancer. These cells harbor integrated human papillomavirus type 18 (HPV18) sequences and express the viral E6 oncoprotein, which inactivates the p53 tumor suppressor, thereby abrogating p53-mediated DNA damage responses. This genetic background renders HeLa cells particularly useful for cancer research, allowing dissection of p53-independent pathways and investigation of oncogenic mechanisms in a robust, easy-to-culture in vitro system.
HNRNPF is an hnRNP family RNA-binding protein that recognizes G-rich motifs in pre-mRNAs to regulate alternative splicing. It interacts with hnRNPA1, hnRNPA2B1, SR proteins, and U2AF to modulate splice site selection, and its activity is regulated by phosphorylation and cellular stress. HNRNPF directs the alternative splicing of downstream targets such as BCL-X, CD44, and FGFR2, thereby influencing apoptosis, cell adhesion, and growth signaling.
In the HeLa context, where p53 function is compromised, HNRNPF-mediated splicing decisions may contribute to the malignant phenotype by altering the expression of splice isoforms that promote proliferation, survival, and metastasis. The knockout of HNRNPF in these cells offers a powerful experimental system to interrogate how splicing dysregulation influences cancer cell behavior independent of p53, and it can uncover vulnerabilities that may be exploited therapeutically. This model is particularly useful for studying cervical cancer pathogenesis and for extending insights to other HNRNPF-associated malignancies, such as lung and breast cancers.
The HNRNPF Knockout HeLa Polyclonal Cells can be utilized in diverse assays. Protein depletion is verified by western blotting; splicing changes are quantified by RT-qPCR or RNA-seq; and protein-RNA interactions are mapped via CLIP-seq. Functional consequences are assessed through cell proliferation and apoptosis assays, enabling applications in cancer research, splicing biology, and drug target validation. For additional details, contact Ascent Research.
